General information about the creation and development of biotechnology firms, GenPharm International, Inc, with a focus on globalization strategy. GenPharm was founded in 1989 and quickly became a pioneer in the field of transgenic animal technology. Between 1991 and 1994, the company has pursued advanced studies in transgenic animal technology, established cooperation agreements with a number of major corporations, and raised millions of dollars. In February 1994, he was GenPharm preparing for initial public offering (IPO) of its shares when a competitor has filed suit, claiming that GenPharm were assigned their trade secrets. GenPharm board decided not to continue with the planned IPO, and the company was forced to reduce the size and change the nature of its activities in 1995 and 1996. In March 1997, the legal situation was resolved with a settlement and cross-license agreement. Shortly thereafter, the board received an offer from a public biotechnology company, Medarex, Inc, GenPharm purchase up to $ 65 million. It ends by asking students to develop recommendations for the Board of GenPharm in connection with the acquisition. "Hide
by George Foster, Andrea Higuera Source: Stanford Graduate School of Business 49 pages. Publication Date: September 5, 2002. Prod. #: IB38-PDF-ENG
Related Case Solutions & Analyses:
Biocon: Interview with Dr. Kiran Mazumdar Shaw CEO Video
Mayhem on Madison (B)
New Frontiers in Target Discovery and Validation
Wal-Mart Neighborhood Markets
Compensation and Performance Evaluation at Arrow Electronics
Intel Capital: The Berkeley Networks Investment
Microsoft’s Financial Reporting Strategy
The Walt Disney Company and Pixar Inc.
Portfolio Assignment
Future of Procurement
